Current and novel therapies in acute GVHD

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 2, 2008, Pages 223-237

  Ho, Vincent T ^a   Cutler, Corey ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

BMT; GVHD; HSCT; stem cell transplant

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; BECLOMETASONE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; IMMUNOMODULATING AGENT; IMMUNOTOXIN; INFLIXIMAB; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENTOSTATIN; PLACEBO; PREDNISOLONE; PREDNISONE; PSORALEN; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VISILIZUMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADRENAL SUPPRESSION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CAPILLARY LEAK SYNDROME; CELL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; INFECTION; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOTHERAPY; MORBIDITY; MORTALITY; MYCOSIS; NAUSEA; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS INFECTION; VIRUS REACTIVATION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ADOPTIVE; PHOTOTHERAPY;

EID: 44249120602     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.02.009     Document Type: Review

References (104)

1. Ferrera J.L.M., and Antin J.H. Pathophysiology of graft-versus-host disease. In: Thomas E.D., Blume K.G., and Forman S.J. (Eds). Hematopoietic stem cell transplantation (1999), Blackwell Scientific Publications, Boston 305-315
2. Wysocki C.A., Jiang Q., Panoskaltsis-Mortari A., et al. Critical role for CCR5 in the function of donor CD4 + CD25 + regulatory T cells during acute graft-versus-host disease. Blood 106 9 (2005) 3300-3307
3. Deeg H.J. How I treat refractory acute GVHD. Blood 109 10 (2007) 4119-4126
4. Bacigalupo A. Management of acute graft-versus-host disease. British Journal of Haematology 137 2 (2007) 87-98
5. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 8 7 (2002) 387-394
6. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76 8 (1990) 1464-1472
7. Van Lint M.T., Uderzo C., Locasciulli A., et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 92 7 (1998) 2288-2293
8. Roy J., McGlave P.B., Filipovich A.H., et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplantation 10 (1992) 77-82
9. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75 4 (1990) 1024-1030
10. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in recipients of marrow from HLA-matched sibling donors. Transplantation 18 (1974) 295-304
11. Van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 107 10 (2006) 4177-4181
12. Dugan M.J., DeFor T.E., Steinbuch M., et al. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Annals of Hematology 75 1-2 (1997) 41-46
13. Graziani F., Van Lint M.T., Dominietto A., et al. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica 87 9 (2002) 973-978
14. Cragg L., Blazar B.R., Defor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 6 4A (2000) 441-447
15. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104 5 (2004) 1559-1564
16. Cahn J.Y., Bordigoni P., Tiberghien P., et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 60 9 (1995) 939-942
17. Martin P.J., Nelson B.J., Appelbaum F.R., et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 88 3 (1996) 824-830
18. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 11 9 (2005) 680-687
19. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109 10 (2007) 4557-4563
20. Carpenter P.A., and Sanders J.E. Steroid-refractory graft-vs.-host disease: past, present and future. Pediatric Transplantation 7 Suppl. 3 (2003) 19-31
21. Hsu B., May R., Carrum G., et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplantation 28 10 (2001) 945-950
22. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77 8 (1991) 1821-1828
23. Arai S., Margolis J., Zahurak M., et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 8 3 (2002) 155-160
24. Khoury H., Kashyap A., Adkins D.R., et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplantation 27 10 (2001) 1059-1064
25. Remberger M., Aschan J., Barkholt L., et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clinical Transplantation 15 3 (2001) 147-153
26. MacMillan M.L., Weisdorf D.J., Davies S.M., et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 8 1 (2002) 40-46
27. Knop S., Hebart H., Gscheidle H., et al. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplantation 36 9 (2005) 831-837
28. Gleixner B., Kolb H.J., Holler E., et al. Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha. Bone Marrow Transplantation 8 2 (1991) 93-98
29. Martin P., Schulman H., Schubach W., et al. Fatal Epstein-Barr virus associated proliferation of donor B-cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Annals of Internal Medicine 101 (1984) 310
30. Knop S., Hebart H., Gratwohl A., et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia 21 8 (2007) 1830-1833
31. Carpenter P.A., Appelbaum F.R., Corey L., et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99 8 (2002) 2712-2719
32. Carpenter P.A., Lowder J., Johnston L., et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 11 6 (2005) 465-471
33. Deeg H.J., Blazar B.R., Bolwell B.J., et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 98 7 (2001) 2052-2058
34. Macmillan M.L., Couriel D., Weisdorf D.J., et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 109 6 (2007) 2657-2662
35. Uchiyama T., Broder S., and Waldmann T.A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. Journal of Immunology 126 4 (1981) 1393-1397
36. Uchiyama T., Nelson D.L., Fleisher T.A., et al. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. Journal of Immunology 126 4 (1981) 1398-1403
37. Queen C., Schneider W.P., Selick H.E., et al. A humanized antibody that binds to the interleukin 2 receptor. Proceedings of the National Academy of Sciences of the United States of America 86 24 (1989) 10029-10033
38. Anasetti C., Martin P.J., Hansen J.A., et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 50 (1990) 49-54
39. Cuthbert R.J.G., Phillips G.L., Barnett M.J., et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplantation 10 (1992) 451-455
40. Hervé P., Wijdenes J., Bergerat J.P., et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 75 (1990) 1017-1023
41. Pinana J.L., Valcarcel D., Martino R., et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 12 11 (2006) 1135-1141
42. Bay J.O., Dhedin N., Goerner M., et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 80 6 (2005) 782-788
43. Anasetti C., Hansen J.A., Waldmann T.A., et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84 4 (1994) 1320-1327
44. Willenbacher W., Basara N., Blau I.W., et al. Treatment of steroid-refractory acute and chronic graft-versus-host disease with daclizumab. British Journal of Haematology 112 3 (2001) 820-823
45. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95 1 (2000) 83-89
46. Massenkeil G., Rackwitz S., Genvresse I., et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplantation 30 12 (2002) 899-903
47. Schmidt-Hieber M., Fietz T., Knauf W., et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. British Journal of Haematology 130 4 (2005) 568-574
48. Funke V.A., de Medeiros C.R., Setubal D.C., et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplantation 37 10 (2006) 961-965
49. Varadi G., Or R., Slavin S., et al. In vivo CAMPATH-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease. American Journal of Hematology 52 3 (1996) 236-237
50. Busca A., Locatelli F., Lovisone E., et al. Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 11 9 (2005) 734-736
51. Wandroo F., Auguston B., Cook M., et al. Successful use of Campath-1H in the treatment of steroid-refractory liver GvHD. Bone Marrow Transplantation 34 3 (2004) 285-287
52. Carella A.M., Beltrami G., Scalzulli P.R., et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplantation 33 1 (2004) 131-132
53. Hale G., Jacobs P., Wood L., et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplantation 26 1 (2000) 69-76
54. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99 12 (2002) 4357-4363
55. Shapira M.Y., Resnick I.B., Bitan M., et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplantation 36 12 (2005) 1097-1101
56. Toor A.A., Stiff P.J., Nickoloff B.J., et al. Alefacept in corticosteroid-refractory graft versus host disease: early results indicate promising activity. The Journal of Dermatological Treatment 18 1 (2007) 13-18
57. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104 4 (2004) 1224-1226
58. Shaughnessey P., Bachier C., Grimley M., et al. Phase II study of denileukin diftitox (ONTAK) in the treatment of steroid resistant acute graft-versus-host disease (AGVHD). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 9 2 (2003) 110 [abstract]
59. Busca A., Locatelli F., Marmont F., et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid-refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. American Journal of Hematology 82 1 (2007) 45-52
60. Wolff D., Roessler V., Steiner B., et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplantation 35 10 (2005) 1003-1010
61. Kennedy G.A., Butler J., Western R., et al. Combination antithymocyte globulin and soluble TNF alpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplantation 37 12 (2006) 1143-1147
62. Hervé P., Flesch M., Tiberghian P., et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79 (1992) 3362-3368
63. Kobbe G., Schneider P., Rohr U., et al. Treatment of severe steroid-refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplantation 28 1 (2001) 47-49
64. Jacobsohn D.A., Hallick J., Anders V., et al. Infliximab for steroid-refractory acute GVHD: a case series. American Journal of Hematology 74 2 (2003) 119-124
65. Yamane T., Yamamura R., Aoyama Y., et al. Infliximab for the treatment of severe steroid-refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leukemia & Lymphoma 44 12 (2003) 2095-2097
66. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 89 11 (2004) 1352-1359
67. Couriel D., Canosa J., Engler H., et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplantation 18 2 (1996) 347-353
68. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients. A cohort study. Blood (2003)
69. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. Journal of Clinical Oncology 23 12 (2005) 2661-2668
70. Basara N., Blau W.I., Kiehl M.G., et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplantation Proceedings 30 8 (1998) 4087-4089
71. Basara N., Kiehl M.G., Blau W., et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplantation Proceedings 33 3 (2001) 2121-2123
72. Krejci M., Doubek M., Buchler T., et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Hematology 84 10 (2005) 681-685
73. Takami A., Mochizuki K., Okumura H., et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology 83 1 (2006) 80-85
74. Baudard M., Vincent A., Moreau P., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplantation 30 5 (2002) 287-295
75. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nature Reviews. Cancer 4 5 (2004) 335-348
76. Baan C.C., van der Mast B.J., Klepper M., et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 80 1 (2005) 110-117
77. Battaglia M., Stabilini A., and Roncarolo M.G. Rapamycin selectively expands CD4 + CD25 + FoxP3 + regulatory T cells. Blood 105 12 (2005) 4743-4748
78. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4 + CD25 + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108 1 (2006) 390-399
79. Hackstein H., Taner T., Logar A.J., et al. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 100 3 (2002) 1084-1087
80. Monti P., Mercalli A., Leone B.E., et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 75 1 (2003) 137-145
81. Hackstein H., Taner T., Zahorchak A.F., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101 11 (2003) 4457-4463
82. Chiang P.H., Wang L., Liang Y., et al. Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic [correction of dendritc] cell function. Transplantation Proceedings 34 5 (2002) 1394-1395
83. Woltman A.M., de Fijter J.W., Kamerling S.W., et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 98 1 (2001) 174-180
84. Woltman A.M., van der Kooij S.W., Coffer P.J., et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 101 4 (2003) 1439-1445
85. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72 12 (2001) 1924-1929
86. Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102 5 (2003) 1601-1605
87. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109 7 (2007) 3108-3114
88. Wiesmann A., Weller A., Lischka G., et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplantation 23 2 (1999) 151-155
89. Furlong T., Leisenring W., Storb R., et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 8 4 (2002) 206-212
90. Wetzig T., Sticherling M., Simon J.C., et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplantation 35 5 (2005) 515-519
91. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 12 1 Suppl. 2 (2006) 7-12
92. Biagi E., Di Biaso I., Leoni V., et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4 + CD25 + GITR + Foxp3 + CD62L + functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 84 1 (2007) 31-39
93. Greinix H.T., Knobler R.M., Worel N., et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 91 3 (2006) 405-408
94. Le Blanc K., and Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 11 5 (2005) 321-334
95. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 9419 (2004) 1439-1441
96. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 10 (2006) 1390-1397
97. Shapira M.Y., Bloom A.I., Or R., et al. Intra-arterial catheter directed therapy for severe graft-versus-host disease. British Journal of Haematology 119 3 (2002) 760-764
98. Tfayli A., Selby G., Maqbool F., et al. Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. American Journal of Hematology 81 12 (2006) 959-962
99. Bloom A.I., Shapira M.Y., Or R., et al. Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial. Clinical Therapeutics 26 3 (2004) 407-414
100. Bertz H., Afting M., Kreisel W., et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplantation 24 11 (1999) 1185-1189
101. Ippoliti C., Champlin R., Bugazia N., et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. Journal of Clinical Oncology 15 11 (1997) 3350-3354
102. Bianco J.A., Higano C., Singer J., et al. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation 49 6 (1990) 1194-1195
103. Nishida T., Hamaguchi M., Hirabayashi N., et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplantation 33 11 (2004) 1143-1150
104. Ruutu T., Eriksson B., Remes K., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 100 6 (2002) 1977-1983